Laboratorios Farmaceuticos Rovi, S.A. (BME: ROVI)

Market Cap	3.22B
Revenue (ttm)	799.25M
Net Income (ttm)	165.00M
Shares Out	51.15M
EPS (ttm)	3.09
PE Ratio	20.38
Forward PE	18.67
Dividend	1.10 (1.78%)
Ex-Dividend Date	Jul 8, 2024

Volume	95,390
Open	61.85
Previous Close	61.85
Day's Range	61.85 - 63.00
52-Week Range	54.00 - 94.80
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About ROVI

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Nepar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1946
• Employees: 2,111
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2023, ROVI's revenue was 829.51 million, an increase of 1.44% compared to the previous year's 817.70 million. Earnings were 170.34 million, a decrease of -14.69%.